|Bid||0.00 x 1100|
|Ask||0.00 x 900|
|Day's Range||93.80 - 97.04|
|52 Week Range||89.65 - 159.54|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||147.00|
Subscribe to Yahoo Finance Plus to view Fair Value for EXASLearn more
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences Corp. (NASDAQ: EXAS) today shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer (CRC) compared to annual fecal immunochemical test (FIT), when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population. Cologuard remained cost-effective in all the real-world adherence scen
It's not that difficult to spread your investments out across many companies and hope for the best over a long time horizon. Another took a different route by making a bet on ARK Genomic Revolution ETF (NYSEMKT: ARKG) in the hope of owning the first healthcare industry trillion-dollar market cap company. Jason Hawthorne (Novo Nordisk): Novo Nordisk is one of three large drug manufacturers that account for the majority of insulin production in the world.